FibroBiologics (FBLG) and Charles River Laboratories (CRL) announced the completion of FibroBiologics’ proprietary master cell bank that will support upcoming clinical trials. Manufactured in accordance with FDA Good Manufacturing Practices, the cell bank has passed all required safety testing. Charles River’s cGMP manufacturing facilities will serve as the production site for the CYWC628 cell banks and drug product for the upcoming phase I/II diabetic foot ulcer clinical trial slated to begin later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- Buy Rating for FibroBiologics, Inc. Driven by Innovative Fibroblast Therapy and Promising Pipeline
- FibroBiologics files $50M mixed securities shelf
- FibroBiologics Approves Executive Bonuses for 2024
- FibroBiologics Secures $5M Funding for Strategic Growth
- FibroBiologics files to sell 41.3M shares of common stock for holders